A response to readers’ comments
Journal of Neuroinflammation volume 15, Article number: 267 (2018)
This is a response to readers’ comments on our paper entitled “Critical role of NLRP3-caspase-1 pathway in age-dependent isoflurane-induced microglial inflammatory response and cognitive impairment” published in the Journal of Neuroinflammation this year.
To the readers and editor,
We appreciate the comments by Yin et al. The focus of our study was to determine whether the nucleotide binding and oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3)-caspase 1 pathway played a role in the primed status of brain cells in aging brain and whether this primed status contributed to isoflurane-induced neuroinflammation and cognitive dysfunction. We provided in vitro and in vivo evidence for these effects. To implicate the role of NLRP3-caspase 1 pathway in the isoflurane effects, we used Ac-YVAD-cmk, a caspase 1 inhibitor, and NLRP3 siRNA. We feel confident that caspase 1 activity is important for the production of interleukin (IL)-18 and IL-1β and that NLRP3 activation is critical for isoflurane-induced caspase 1 activation. The evidence to support these points is in figure 2 and figure 6, respectively, of our publication .
We agree that MCC950 may be an additional tool to probe the role of NLPR3 in isoflurane effects. The proposal that pyroptosis contributes to isoflurane-induced cognitive impairment is interesting. However, our study did not show any effects on cell viability up to 12 h after NLRP3 was activated. However, it will be interesting to know whether NLRP3 inflammasome-dependent pyroptosis is involved in age-dependent isoflurane-induced cognitive impairment. These interesting ideas/proposals require experiments to test.
Nucleotide binding and oligomerization domain-like receptor family pyrin domain-containing 3
Wang Z, Meng S, Cao L, Chen Y, Zuo Z, Peng S. Critical role of NLRP3-caspase-1 pathway in age-dependent isoflurane-induced microglial inflammatory response and cognitive impairment. J Neuroinflammation. 2018;15(1):109.
Ethics approval and consent to participate
Consent for publication
All authors agree to the last version of the manuscript is consent for its publication in the Journal of Neuroinflammation.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Zuo, Z., Wang, Z., Meng, S. et al. A response to readers’ comments. J Neuroinflammation 15, 267 (2018). https://doi.org/10.1186/s12974-018-1300-8